Sean McCarthy, CytomX CEO
Reeling from PhII flop, CytomX lays off 40% as execs go back to drawing board, seek new deals
Just days after putting a lead drug on the backburner in the wake of a Phase II flop, CytomX has settled on a makeover plan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.